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Abstract
Pulmonary fibrosis is an untreatable, uniformly fatal disease of unclear etiology that is the result of unremitting chronic
inflammation. Recent studies have implicated bone marrow derived fibrocytes and M2 macrophages as playing key roles in
propagating fibrosis. While the disease process is characterized by the accumulation of lymphocytes in the lung
parenchyma and alveolar space, their role remains unclear. In this report we definitively demonstrate the ability of T cells to
regulate lung inflammation leading to fibrosis. Specifically we demonstrate the ability of intranasal vaccinia vaccination to
inhibit M2 macrophage generation and fibrocyte recruitment and hence the accumulation of collagen and death due to
pulmonary failure. Mechanistically, we demonstrate the ability of lung Th1 cells to prevent fibrosis as vaccinia failed to
prevent disease in Rag2/2 mice or in mice in which the T cells lacked IFN-c. Furthermore, vaccination 3 months prior to the
initiation of fibrosis was able to mitigate the disease. Our findings clearly demonstrate the role of T cells in regulating
pulmonary fibrosis as well as suggest that vaccinia-induced immunotherapy in the lung may prove to be a novel treatment
approach to this otherwise fatal disease.
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Introduction
Pulmonary fibrosis is a progressive, fatal disease that primarily
affects elderly patients and is due to dysregulated chronic
inflammation of the lungs. Currently there are no effective
treatments for this disease. A critical barrier to treating this disease
is the lack of understanding of the pathophysiology driving the
fibrosis. Normally, inflammation in the lungs is a self-limiting
process that does not result in scarring or fibrosis. In pulmonary
fibrosis however, an unclear initial insult leads to unremitting
inflammation characterized by persistent inflammatory cell in-
filtration, fibroblast recruitment and ensuing fibrosis [1,2]. While
the precise mechanism leading to the development of and
persistence of pulmonary fibrosis is unclear, it is clear that this
disease is associated with the persistence of pro-inflammatory
cytokines and chemokines. Specifically, TNF-a, TGB-b, and both
CXC chemokines (IL-8, MIG, IP-10, I-TAC) as well as CC
chemokines (MIP-1a, MCP-1) [3]. Additionally, there appears to
be a type-2 inflammatory pro-fibrotic response characterized by
IL-4 and IL-13 [4,5,6,7].
In both human and animal models, pulmonary fibrosis has been
associated with T cell infiltrates in the parenchyma and alveolar
space [8,9]. The increased lymphocytes appear to be predomi-
nantly perivascular and in areas of greatest fibrosis and
honeycombing [8,10,11]. However, the precise role of these cells
in either accelerating or inhibiting the development of fibrosis
remains unclear. Contradictory data both supports that T cells
have the ability to modulate bleomycin induced pulmonary
fibrosis as well as that T cells have no role in bleomycin induced
lung disease [12,13,14,15,16,17]. BALB/c mice, which are
naturally resistant to bleomycin-induced lung injury, are rendered
susceptible if pre-treated with cyclophosphamide, a drug that
depletes T cells [17]. Furthermore, if these cyclophosphamide
treated mice are reconstituted with untreated donor BALB/c
splenocytes, the resistance to bleomycin is re-established [17].
However, if they are reconstituted with donor spleens depleted of
T cells, they remain susceptible [17]. These data support the idea
that T cells protect against bleomycin-induced lung injury. Other
studies however demonstrate that depletion of all T cells with
depleting antibodies can make the disease worse or can have no
effect [13,18]. The data using genetically modified mice are also
contradictory in that both SCID and nude mice are equally
susceptible to bleomycin as wild type mice [12,14,16]. However,
CD28 null mice, which cannot fully activate their T cells due to
lack of co-stimulation, have a marked attenuation of injury after
bleomycin [19].
In as much as T cells are a prominent feature of this disease,
these seemingly contradictory data may reflect the fact that
different CD4
+ T cell effector subsets have the ability to either
accelerate or mitigate disease. It has become clear that there is
great plasticity amongst CD4
+ T cells with regard to the
development of specific effector subsets. Indeed, the pathogenesis
of pulmonary fibrosis has been associated with both Th2 and
Th17 T cell subsets [7,20]. Thus we propose a model whereby
during normal lung inflammation T cells regulate immunity to
prevent fibrosis, while in dysregulated immunity T cell effectors
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31299contribute to fibrosis. As such, we posited that the generation of
robust Th1 mediated immunity in the lung might serve to inhibit
the chronic inflammation leading to fibrosis. In this report we
demonstrate that intranasal delivery of live vaccinia vaccine has
the ability to arrest and markedly inhibit the development of
pulmonary fibrosis. Overall these findings provide insight into the
disease process as well as suggest a novel immunotherapeutic
approach to treating and preventing Idiopathic Pulmonary
Fibrosis.
Results
Intranasal Vaccinia enhances survival following
bleomycin challenge
In spite of the observation that there is an accumulation of T
cells in the lung parenchyma and alveolar space of patients with
pulmonary fibrosis, the precise role of T cells in the development
of this disease is currently unclear. However, a role for IL-4, IL-13,
IL-10 and IL-17 in promoting fibrosis has been described [7]. We
hypothesized that the development of a Th1 immune response in
the lungs may inhibit the production and activity of these pro-
fibrotic cytokines. Vaccinia virus was originally developed as
a means of inducing protective immunity against small pox.
Vaccination with live vaccinia leads to robust Th1 responses [21].
We utilized a genetically modified vaccinia that contains the full
length ovalbumin protein but lacks lytic ability. The ovalbumin
was included in the construct as a model cognate antigen and thus
allows us to easily track the antigen specific anti-viral immune
response. Thus, female C57BL/6 mice were intranasally vacci-
nated with two million vaccinia particles that express the full
length ovalbumin protein or mock vaccinated with PBS. Seven
days after the vaccinia vaccination, the mice were given bleomycin
by tracheal cut-down and monitored for weight change and
survival (Figure 1A & B). As predicted for this model, mice that
were initially vaccinated with PBS demonstrated marked weight
loss, indicative of disease. After 20 days post-bleomycin, over 50%
of the PBS-bleomycin mice had succumbed to pulmonary fibrosis
(Figure 1B). However, the mice that were vaccinated with vaccinia
were relatively resistant to the disease process (as determined by
weight loss) and demonstrated a marked increase in survival (only
10% mortality by Day 20). Histologic examination of the lungs
revealed that the decrease in weight and survival in the PBS-
bleomycin treated lungs was associated with a marked increase in
the development of lung fibrosis (Figure 1C). Thus, intranasal
vaccinia vaccination protects mice from the development of
bleomycin-induced chronic inflammation leading to the develop-
ment of fibrosis.
Intranasal vaccinia vaccination induces a Th1 response in
the lungs
We hypothesized that intranasal vaccinia administration would
lead to a pulmonary Th1 response that in turn would abrogate the
dysregulated inflammation leading to fibrosis. To test this, Ova
specific OT-II T cells were transferred into C57BL/6 mice that
were then intranasally vaccinated with vaccinia or PBS. Three days
later lungs were isolated and single cell suspensions were assessed by
FACS. Intranasal vaccinia vaccination led to a marked increase in
the Thy1.1
+ Ova specific T cells to the lungs (Figure S1). Such
findings demonstrate the abilityof intranasalvacciniavaccination to
generate antigen specific CD4
+ T cell responses in the lungs.
Next, we wanted to determine the effector phenotype of these
cells when vaccination was followed by bleomycin exposure. Mice
were vaccinated on day 27 and challenged with bleomycin on day
0 as previously described, lungs were isolated and single cell
suspensions were analyzed for CD4
+ and CD8
+ T cells
percentages by flow cytometry on days 0, 3, 7, and 14
(Figure 2A). Interestingly, total lung cell numbers were unchanged
with or without vaccinia treatment prior to bleomycin adminis-
tration (day 0). That is, seven days post intranasal vaccination, the
total cell numbers from the PBS treated mice and vaccinia treated
mice were equivalent. Following bleomycin challenge, vaccinia
treated mice had a small but significant increase in total lung cell
numbers, however by day seven this trend was reversed and in fact
the PBS treated mice displayed increase cellularity in their lungs
post-bleomycin exposure. When examining T cells, vaccinia
treated mice had greater numbers of CD4
+ and CD8
+ T cells
on day three following bleomycin than mock (PBS) treated mice
(Figure 2B). CD4
+ T cell numbers remained higher at day seven
whereas CD8
+ T cell numbers were equivalent between vaccinia
and mock (PBS) treated mice. Whereas CD8
+ T cell numbers were
equivalent, the percentage of CD8
+ T cells at day seven was seen
to be approximately three times higher in vaccinia treated mice
than mock (PBS) vaccinated mice (Figure 2C). Thus, intranasal
vaccinia vaccination had a minimal effect on the total number of
cells in the lungs of mice post-bleomycin treatment but appeared
to slightly alter the kinetics of the appearance of CD4
+ and CD8
+
T cells during the acute (0–7 days) inflammatory response to
bleomycin.
Figure 1. Vaccinia vaccinated mice have enhanced survival
following bleomycin administration. A. Weight changes in vaccinia
vaccinated and mock (PBS) vaccinated mice following bleomycin
administration. B. Survival curves of vaccinia vaccinated and mock
(PBS) vaccinated mice following bleomycin administration. C. Masson-
Trichrome staining of lungs of PBS and vaccinia treated mice on day 14.
Error bars indicate one standard deviation of the mean and (*) indicates
statistical significance (p,.05) between groups. All experiments were
performed at least three times, at least 10 animals per group per
experiment.
doi:10.1371/journal.pone.0031299.g001
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vaccinated and mock (PBS) vaccinated mice post-bleomycin
exposure, we next sought to determine the nature of the
inflammatory response in these two groups. We hypothesized that
vaccinia would promote a Th1 response in the lungs and therefore
we analyzed lung CD4
+ as well as CD8
+ T cells for their ability to
produce IFNc. CD4
+ and CD8
+ T cells were isolated from the
lungs of treated mice and analyzed by FACS for their ability to
produce IFN-c (Figure 2D). T cells derived from the lungs of the
vaccinia-treated mice demonstrated robust production of IFN-c
on days 3, 7 and 14 post-bleomycin exposure. In contrast there
was very little production of IFN-c by T cells isolated from the
lungs of the unvaccinated mice. Consistent with this increase in
IFN-c producing T cells, there was an increase in IFN-c in the
BAL fluid from the vaccinia vaccinated mice which peaked at day
3 post-bleomycin exposure (Figure 2E). Recent studies have
demonstrated a role for IL-17 in promoting the pathogenesis seen
in the bleomycin exposure model [20]. As such, we wanted to
determine the effect of vaccinia vaccination on the generation of
Th17 cells post-bleomycin exposure. Lungs from either mock
(PBS) vaccinated or vaccinia treated mice were isolated on days 0,
3, 7, and 14 post bleomycin administration and ICS was
performed on CD4
+ T cells for IL17 (Figure 2F). Consistent with
previously published studies, mock (PBS) vaccinated bleomycin
exposed mice had increased numbers of IL17
+ CD4
+ T cells at all
time points analyzed [20]. Alternatively, the induction of Th17
cells was markedly mitigated in the vaccinated mice. Thus,
intranasal vaccinia vaccination led to both increased Th1
responses and decreased Th17 responses in the lungs post
bleomycin-exposure.
Vaccinia vaccination promotes an M1 macrophage
response
Macrophages are present in significant numbers in the normal
lung and increase dramatically upon lung inflammation. Indeed,
macrophages are believed to play a critical role in promoting the
chronic inflammation leading to lung fibrosis. Specifically, recent
studies have suggested that M2 macrophages play a role in
promoting the development of fibrosis [22,23]. The development
of M2 macrophages is associated with a Th2 environment
including the profibrotic chemokines IL-4 and IL-13 [24]. Thus
we wanted to determine the effect of vaccinia vaccination on M2
macrophage development.
First, we analyzed the effect of vaccinia vaccination on
macrophage recruitment upon bleomycin exposure. C57BL/6
mice were vaccinated as previously described and bleomycin was
instilled intratracheally seven days later. On days 0, 3, 7, and 14
following bleomycin challenge lungs were isolated, processed to
single cell suspensions and stained for the presence of CD11b
+
macrophages (Figure 3A). As was seen with T cells in the lungs, the
number of macrophages was not significantly changed following
vaccinia treatment prior to bleomycin challenge when compared
to mock (PBS) vaccinated mice at day 0. After bleomycin, the
vaccinia treated mice did display an early significant increase in
CD11b
+ lung cells, however macrophage numbers did not
increase significantly on days 7 and 14. Mock (PBS) vaccinated
mice had significantly increased lung CD11b
+ macrophages on
day 7 and day 14 after bleomycin, approximately 2 fold more than
vaccinia treated mice. Overall, while vaccinia treated mice had an
earlier increase in macrophages in the lung after bleomycin, later
time points did not show protracted total macrophage numbers
when compared to mock (PBS) vaccinated mice that received
bleomycin.
Next, we examined the effect of vaccinia vaccination on
macrophage subsets post bleomycin exposure. To examine lung
M1 macrophages we performed ICS for IFNc on CD11b
+
macrophages on days 0, 3, 7, and 14 following bleomycin
challenge on both mock (PBS) vaccinated and vaccinia vaccinated
mice (Figure 3B). Lungs of vaccinia treated mice had increased
numbers of IFNc
+ CD11b
+ macrophages prior to bleomycin
challenge on day 0, indicating that vaccinia vaccination alone was
activating some macrophages. There were significantly more
IFNc
+ CD11b
+ macrophages on day 3 in the lungs of vaccinia
treated mice when compared to mock (PBS) vaccinated mice,
however by day 7 the numbers of lung IFNc
+ CD11b
+
macrophages were not significantly different between the two
groups. Similar to CD4
+ and CD8
+ T cells, vaccinia treated mice
maintained a higher number of IFNc
+ CD11b
+ macrophages on
day 14 than mock (PBS) vaccinated. Overall, vaccinia treatment
induced an earlier population of IFNc
+ CD11b
+ macrophages,
and maintained a larger population of these cells at day 14.
Recently the mannose receptor (CD206) has been shown to be
a surface marker for M2macrophagesinmultipleinvivo models[24].
Therefore, we chose to analyze the expression of CD206 on
macrophages following bleomycin challenge on both mock (PBS)
vaccinated and vaccinia vaccinated mice (Figure 3C). On days 3, 7,
and 14 mock (PBS) vaccinated mice displayed significantly increased
numbers of CD206
+ CD11b
+ cells whereas vaccinia treated mice
displayed relatively low levels of CD206
+ CD11b
+ macrophages. In
addition to CD206, we analyzed the expression of other markers of
M2 macrophages. To accomplish this RNA was isolated from lungs
of mice on days 0, 3, 7 and 14 following bleomycin administration.
Real time PCR was performed on lung cDNA to determine the
expression of the M2 markers Arg1 and Fizz1 (Figures 3D, E). RNA
for both Arg1 and Fizz1 was significantly increased in PBS treated
mice which received bleomycin whereas Arg1 and Fizz1 expression
remained low in vaccinia vaccinated mice. These data indicate that
M2 macrophages are present at high levels following bleomycin
challenge and that vaccinia vaccination suppresses the development
of these cells. Overall, vaccinia vaccination promotes an M1
phenotype in lung macrophages following bleomycin challenge.
That is, intranasal vaccinia vaccination prior to bleomycin exposure
creates an immune microenvironment that fosters the generation of
M1 macrophages rather than M2 macrophages upon bleomycin
exposure.
Vaccinia vaccination abrogates lung fibrocyte
accumulation in bleomycin-induced pulmonary fibrosis
Intratracheal bleomycin induces pulmonary fibrosis through the
deposition of collagen that distorts the architecture of the lung and
Figure 2. Vaccinia vaccinated mice display greater lung T cell numbers and enhanced function following bleomycin challenge. A.
Total lung cell numbers of vaccinia vaccinated and mock (PBS) vaccinated mice following bleomycin administration. B. Total CD4
+ and CD8
+ T cells
present in the lung following bleomycin administration. C. Flow cytometric analysis of percentages of lung CD4
+ and CD8





+ T cells following bleomycin administration. E. ELISA analysis of IFNc concentration in bronchial lavage fluid following bleomycin
administration. F. Total lung CD4
+ IL17
+ T cells following bleomycin administration. Error bars indicate one standard deviation of the mean and (*)
indicates statistical significance (p,.05) between groups. All experiments were performed at least three times, at least 10 animals per group per
experiment.
doi:10.1371/journal.pone.0031299.g002
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vaccination enhanced survival and maintenance of weight
following bleomycin challenge (figure 1). Interestingly, vaccination
did not inhibit inflammation (inflammatory cell recruitment to the
lungs was not inhibited) but rather vaccination promoted the
induction of a robust Th1 response. We next wanted to determine
the mechanism by which Th1 cells might prevent fibrosis.
Recently, CD45
+ collagen
+ fibrocytes have been implicated in
playing an important role in elaboration of extracellular matrix
leading to pulmonary fibrosis [25,26]. In vitro, it has been
demonstrated that Th1 responses inhibit fibrocyte differentiation
[27]. Thus, we wanted to determine if vaccinia vaccination
inhibited fibrocyte accumulation in the lungs. To address this,
C57BL/6 mice were vaccinated with vaccinia or mock vaccinated
with PBS and seven days later bleomycin was instilled intra-
tracheally. Lungs were isolated and histology was performed on
days 0, 7, and 21 (Figure 4A). Prior to bleomycin challenge, the
lungs of vaccinia vaccinated mice displayed normal architecture
with no significant inflammatory cell infiltrate, indicating that the
dose of vaccinia utilized did not alter lung architecture or function.
Such findings were consistent with the Day 0 FACS analysis of
BAL fluid (Figure 2). Seven days after bleomycin challenge the
lungs of mock (PBS) vaccinated mice displayed peribronchial
monocytic and lymphocytic infiltrate and some scant hemorrhage
and alveolar infiltration. In comparison, the lungs of vaccinia
vaccinated mice had drastically reduced peribronchial infiltrate.
Fibrocytes are differentiated from bone marrow derived mono-
cytes and histological analysis of the lungs from vaccinated mice
demonstrated decreased recruitment of hematopoietically-derived
cells. Furthermore, lungs of day 21 mock (PBS) vaccinated mice
displayed dense cellular consolidation with protein deposition,
interstitial thickening and airspace effacement, all characteristic of
bleomycin-induced pulmonary fibrosis. In contrast, lungs of
vaccinia vaccinated mice displayed dramatically reduced peri-
bronchial and airspace infiltration without significant consolida-
tion or protein deposition. In addition, we wanted to examine the
deposition of collagen in the vaccinia and mock (PBS) vaccinated
mice. To accomplish this, lungs were isolated 3, 7, and 14 days
following bleomycin challenge with or without vaccinia vaccina-
tion, and total lungs were subjected to hydroxyproline analysis
(Figure 4B). There were similar levels of collagen in vaccinia
vaccinated and mock (PBS) vaccinated mice on days 3 and 7.
However on day 14 the collagen levels of vaccinia vaccinated mice
remained constant whereas the collagen levels of mock (PBS)
vaccinated mice increased two fold. These histologic data
demonstrate that the ability of vaccinia vaccination to protect
against bleomycin-induced pulmonary fibrosis is associated with
interruption of the late (persistent) inflammation leading to fibrosis.
In as much as fibrocytes are believed to play an important role
in chronic inflammation leading to fibrosis, we next directly
examined the effect of vaccinia vaccination on lung fibrocyte
accumulation post-bleomycin exposure. Lung single cell suspen-
sions were stained with CD45 and collagen and analyzed by flow
cytometry (Figure 4C). Mock (PBS) vaccinated mice had
a significantly higher percentage of fibrocytes in the lung following
bleomycin when compared to the vaccinia treated mice on day 7.
In addition, total fibrocyte numbers were significantly greater at
days 3, 7, and 14 following bleomycin in the mock (PBS)
vaccinated mice.
T cell specific inhibition of fibrosis
Immunotherapy in the form of vaccinia vaccination leads to
decreased M2 macrophages, decreased fibrocytes and ultimately
decreased fibrosis upon bleomycin induced lung injury. We next
wanted to definitively demonstrate that this protective effect was
indeed due to the vaccinia-induced T cell response. To test this,
bleomycin was administered to mice lacking T cells in combina-
tion with mock (PBS) vaccine or vaccinia vaccine. Wild type and
Figure 3. Vaccinia vaccinated mice have greater numbers of
lung M1 macrophages and fewer lung M2 macrophages. A.
Total lung CD11b
+ cells following bleomycin administration. B. Total
lung CD11b
+ IFNc
+ cells following bleomycin administration. C. Total
lung CD11b
+ CD206
+ cells following bleomycin administration. D.
Arginase1 RNA expression from lung tissue. E. Fizz1 RNA expression
from lung tissue. Error bars indicate one standard deviation of the mean
and (*) indicates statistical significance (p,.05) between groups. All
experiments were performed at least three times, at least 10 animals
per group per experiment.
doi:10.1371/journal.pone.0031299.g003
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vaccinated with vaccinia, and seven days later bleomycin was
administered intranasally. Mouse survival was recorded over three
weeks (Figure 5A). Wild type mice that received vaccinia prior to
bleomycin were protected from fibrosis and had 100% survival
while only 50% of wild type mice that were mock (PBS) vaccinated
survived. Rag null mice that received a mock (PBS) vaccination
prior to bleomycin displayed earlier mortality than wild type mock
(PBS) vaccinated mice and decreased survival overall. Interesting-
ly, Rag null mice which received vaccinia prior to bleomycin had
100% mortality by day 11, indicating that in the absence of T cells
vaccinia induces lethal inflammation in the lung. Overall, these
data support our hypothesis that the inhibition of fibrosis observed
in our model is T cell driven.
Next we wanted to demonstrate that it was specifically the
vaccinia-induced Th1 response that prevented fibrosis. To this
end, Rag mice were reconstituted with 2 million wild type CD4
+ T
cells and 2 million wild type CD8
+ T cells or 2 million IFNc null
CD4
+ T cells and 2 million IFNc null CD8
+ T cells. Seven days
after the T cell transfer flow cytometry for CD4
+ and CD8
+ T cells
was performed on tail blood to ensure equivalent T cell
reconstitution (Figure 5B). Transferred wild type and IFNc null
T cells were equally efficient in reconstituting the T cell
compartment of Rag null mice. Further, T cell reconstitution
mimicked CD4 and CD8 ratios seen in wild type C57B6 mice. All
mice were subsequently vaccinated with vaccinia and then 7 days
later received intratracheal bleomycin. Vaccinia vaccinated Rag
null mice that received wild type CD4
+ and CD8
+ T cells had
100% survival following bleomycin challenge (Figure 5C). How-
ever, vaccinated Rag null mice that received IFNc null CD4
+ and
CD8
+ T cells demonstrated only 50% survival. That is in the
absence of T cell derived IFN-c, the vaccine was ineffective. This
is in spite of the fact that other bone marrow derived cells are IFN-
c competent.
Next we correlated IFNc dependent survival with macrophage
and T cell function. Cells were isolated from the lungs of mice that
had received wild type or IFN-c null T cells and analyzed on day
7. CD4
+ T cells from mice which received IFNc null T cells had
twice the percentage of IL17
+ CD4
+ T cells than mice which
received wild type T cells (Figure 5D). That is, vaccinia-induced T
cell derived IFN-c inhibited the generation of the Th17 response
in the lungs of mice treated with bleomycin. When we examined
macrophages, we found that the vaccinia-induced Th1 response
also played an important role in skewing toward a protective M1
macrophage response. Indeed, vaccinia vaccinated mice that were
reconstituted with IFN-c null T cells, failed to generate M1
macrophages.
Vaccinia vaccination provides long term resistance to
bleomycin induced pulmonary fibrosis
Our data demonstrate that intranasal vaccinia vaccination 7
days prior to bleomycin exposure induces a Th1 response in the
lungs that is able to mitigate the dysregulated inflammation that
Figure 4. Vaccinia vaccination abrogates bleomycin induced
pulmonary fibrosis. A. Histological analysis of lungs of vaccinia
vaccinated and mock (PBS) vaccinated mice following bleomycin
administration. B. Total lung collagen concentration following bleomy-
cin administration. C. Flow cytometry and graphical analysis of fibrocyte
(CD45
+, Collagen
+) numbers in lungs of mice 7 days after bleomycin
administration. Error bars indicate one standard deviation of the mean
and (*) indicates statistical significance (p,.05) between groups. All
experiments were performed at least three times, at least 10 animals
per group per experiment.
doi:10.1371/journal.pone.0031299.g004
Vaccination Prevents Lung Fibrosis
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31299leads to fibrosis. Such findings provide important insight in terms
of the role of Th1 T cells in regulating lung inflammation.
However, we also wanted to know the potential duration of the
vaccinia effect. To address this, C57BL\6 mice were given mock
(PBS) or vaccinia vaccine and then exposed to bleomycin 6, 8, and
12 weeks later (Figure 6). In each instance, mice that received
vaccinia vaccination had greater survival than mock (PBS)
vaccinated mice. That is, intranasal vaccinia vaccination mitigated
death due to pulmonary fibrosis even when there was 3 months
between the vaccine and bleomycin exposure. Interestingly, as
times between vaccination and bleomycin challenge increased so
did the overall mortality in response to bleomycin. We believe that
this finding is consistent with the observation that older mice are
more susceptible to bleomycin-induced pulmonary fibrosis [28].
Nonetheless, in spite of the overall increase in mortality in the
older mice, the vaccinia vaccination was still able to mitigate
disease.
Discussion
Pulmonary fibrosis is a common, often fatal, poorly treatable
final end point for a diverse group of pulmonary diseases. It is
characterized by the recruitment and proliferation of fibroblasts,
lung myofibroblasts, epithelial-mesenchymal transition and bone
marrow derived fibrocytes leading to the deposition of excess
extracellular matrix and the subsequent destruction of the lung
parenchyma. This process is driven by dysregulated chronic
inflammation leading to the elaboration of profibrotic chemokines
and cytokines. The study of human pulmonary fibrosis has been
complicated by the unknown etiology, variable natural history,
advanced disease at presentation and the insidious progression of
fibrosis over years and even decades. In this paper we utilized the
bleomycin model of lung fibrosis. Although no animal model of
lung fibrosis is perfect, the bleomycin model is a well-established,
well-studied, reproducible model of murine lung fibrosis that can
be interrogated to reveal potential mechanisms underlying human
fibrotic lung disorders [20,29,30,31]. We hypothesized that the
dysregulated inflammation leading to fibrosis might be regulated
by the presence of disease inhibiting T cells. Indeed, immuno-
therapy in the form of vaccinia vaccination mitigated lung fibrosis
in the bleomycin mouse model of disease. Mechanistically, this
form of immunotherapy was shown to be dependent on T cell
derived IFN-c and resulted in a marked decrease in the
recruitment of M2 macrophages, fibrocytes and subsequent
collagen deposition. Overall these findings provide important
insight in terms of the ability of Th1 effector T cells to regulate
disease as well as suggest a novel treatment approach.
In light of the fact that the lungs are constantly exposed to the
outside environment, the pulmonary immune response is both
varied and robust. Pro-inflammatory cytokines and chemokines
are produced by not only bone marrow derived resident lung
macrophages and dendritic cells, but also by epithelial cells lining
Figure 5. T cell derived IFNc is necessary for protection from
bleomycin induced fibrosis. A. Survival curves of wild type and Rag
null mice following vaccinia vaccination or mock (PBS) vaccination and
bleomycin administration. B. Flow cytometric analysis of T cell
reconstitution of Rag null mice. C. Survival curves of Rag null mice
reconstituted with either wild type of IFNc null CD4
+ and CD8
+ T cells.
All mice were vaccinated with vaccinia and bleomycin was adminis-





cells. E. Flow cytometric analysis of lung CD11B
+ IFNc
+ cells. Histograms
are gated on CD11b
+ cells. All experiments were performed at least
three times, at least 10 animals per group per experiment.
doi:10.1371/journal.pone.0031299.g005
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responses as well as the upregulation of the adaptive immune
response. The development of fibrosis has generally been
associated with cytokines and chemokines that are primarily
associated with a Th2 type response [7]. Indeed, IL-4 and IL-13
have been described in lungs from patients with Idiopathic
Pulmonary Fibrosis and contribute to the development of fibrosis
in a number of mouse models [34,35]. For example, the IL-4
receptor is present on lung fibroblasts and IL-4 has been shown to
promote the deposition of extracellular matrix proteins, collagen
and subsequent fibrosis [7]. Further, IL-4 can promote the
generation of M2 macrophages, which can facilitate fibrosis in part
through the elaboration of TGF-b and PDGF [34]. M2
macrophages have been shown to be increased in the lungs of
Idiopathic Pulmonary Fibrosis patients as well as in the lungs of
bleomycin treated mice [23,36]. Indeed, in our model, intranasal
vaccinia vaccination abrogated the increase in M2 macrophages
upon bleomycin treatment. Recent studies have also demonstrated
a role for IL-10 in both fibrocyte recruitment and alternatively
activated macrophage activation in the bleomycin model [22].
Finally, IL-17 has also been shown to play a role in the
pathogenesis of bleomycin-induced lung fibrosis [20]. It was found
that IL-1 produced by both Th17 and cd T cells lead to increased
neutrophilia and fibrosis in lungs of bleomycin treated mice [20].
Taken together these studies emphasize the potential role of T
cell mediated immunity in promoting fibrosis. Studies designed to
determine the precise role of T cell effector subsets in the
development of fibrosis have been confusing. Simplistic models
have focused on the role of IFN-c in preventing fibrosis. Indeed,
patients with progressive Idiopathic Pulmonary Fibrosis and
scleroderma-pulmonary fibrosis have decreased IFN-c in their
bronchoalveolar lavage fluid [37,38,39,40]. Early clinical trials
with systemic IFN-c looked promising but ultimately failed to
demonstrate efficacy possible due to off target effects of systemic
delivery (for example the activation of macrophages, NK cells and
neutrophils) [37,41,42]. By employing genetically modified mice,
the contribution of Th1 and Th2 cytokines has also been
investigated in the past without yielding a clear role. Using the
bleomycin model there are studies demonstrating increased disease
in mice that over-express the Th2 transcription factor GATA-3
while other studies show decreased disease in IL-4 over-expressing
mice [4,43]. Alternatively, there are studies showing increased
disease in Th1 compromised mice (T-bet null, IL-12 null) while
other studies show decreased disease or no effect on disease in
IFN-c null mice [44,45,46,47]. Further, some studies have shown
that treatment with IFN-c, IP-10 or IL-12 can mitigate disease
[48,49] while others show less disease in mice treated with anti-IL-
12 [50]. We believe that these conflicting results reflect the fact
that systemic deletion or over-expression of cytokines can affect
both the initial inflammatory insult and the chronic fibrosis-
inducing process. This is seen in the studies of Pham et al. who
demonstrated that IL-4 both inhibited the initial inflammation to
bleomycin (without the initial inflammation there is no chronic
fibrosis) and enhanced the fibrogenic process [5]. Thus with rare
exceptions, these cited studies do not specifically examine the role
of discrete T helper cell subsets to regulate fibrosis, but rather the
global effects of cytokines without distinguishing between the
effects on the initial inflammation and the chronic fibrogenic
process.
Since both Th2 and Th17 mediated immune responses have
been implicated in promoting the chronic inflammation leading to
lung fibrosis, we hypothesized that the generation of Th1 effector
responses in the lung might prevent this process. Our data
demonstrate that intranasal delivery of vaccinia virus was able to
prevent the development of fibrosis upon bleomycin exposure. As
its name implies, vaccinia virus was developed as a means of
inducing protective immunity against small pox. By employing an
ova expressing vaccinia construct, we were able to demonstrate
that the protection against fibrosis is commensurate with the
generation of an antigen specific Th1 response in the lungs. The
vaccine failed to protect when Rag
2/2 mice were reconstituted
with T cells lacking IFN-c. Importantly, these latter findings
demonstrate the specific role of T cells (and T cell derived IFN-c)
in inhibiting fibrosis. That is, in spite of the fact that all of the other
cells in the lungs were capable of producing IFN-c, protection was
not observed in the absence of IFN-c producing T cells. These
observations accentuate the immunoregulatory capability of T
helper cells in this model and provide a partial explanation as to
why a trial employing systemic IFN-c treatment failed to impact
disease in idiopathic pulmonary fibrosis patients [51].
Data are emerging implicating an important role for bone
marrow-derived fibrocytes in driving lung fibrosis [52]. Fibrocytes
normally make up 0.1–1% of nucleated cells in the blood [53]. In
addition to CD45 they express various chemokine receptors
including CXCR4 which promotes their migration to inflamed
lungs in response to CXCL12 gradients [25,26]. In both the
bleomycin model and human Idiopathic Pulmonary Fibrosis,
fibrocytes are believed to play a critical role in laying down
collagen leading to fibrosis [26,54]. Levels of peripheral blood
fibrocytes have been shown to correlate with disease activity in
Figure 6. Vaccinia vaccination provides long term protection
against bleomycin induced pulmonary fibrosis. Survival curves of
mice vaccinia vaccinated or mock (PBS) vaccinated either six weeks (A.)
eight weeks (B.) or twelve weeks (C.) prior to bleomycin administration.
All experiments were performed at least three times, at least 10 animals
per group per experiment.
doi:10.1371/journal.pone.0031299.g006
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with their role in promoting lung fibrosis, the ability of vaccinia
vaccination to inhibit disease was associated with a decrease in the
number of lung fibrocytes in response to bleomycin. Interestingly,
Shao et al. have shown that Th1 cytokines inhibit fibrocyte
differentiation while Th2 cytokines promote fibrocyte generation
from peripheral blood monocytes [27]. Thus mechanistically, our
data suggest that the ability of Th1 induced immunotherapy to
prevent pulmonary fibrosis is in part through the inhibition of
fibrocyte differentiation in the lungs.
There is currently no effective treatment for pulmonary fibrosis.
Based on our findings, we propose enforced skewing of T helper
cell responses as a novel form of immunotherapy to mitigate the
development of lung fibrosis. Interesting, we demonstrate that
a single vaccination with vaccinia was able to mitigate bleomycin-
induced lung injury and death up to 12 weeks after vaccination.
Such observations suggest that vaccination and subsequent
enforced T helper cell skewing may have the ability to both
prevent and more importantly arrest the development of fibrosis
even after the initial insult.
Materials and Methods
Mice
All animal protocols were approved by the Institutional Animal
Care and Use Committee of Johns Hopkins University (Baltimore,
MD). C57BL/6, B6.129S7-Rag1tm1Mom/J, and B6.129S7-
Ifngtm1Ts/J were purchased from The Jackson Laboratory (Bar
Harbor, ME). C57BL/6 Thy1.1
+, OTII
+ mice were generated by
crossing C57BL/6 Thy1.1
+ and C57B6 OTII
+ mice purchased
from The Jackson Laboratory (Bar Harbor, ME).
Reagent
Vaccinia was generated as previously described [57]. Bleomycin
was purchased from App pharmaceuticals, (Schaumburg, IL).
PMA and Ionomycin were purchased from Sigma-Aldrich
(Milwaukee, WI). Flow cytometry antibodies and reagents were
purchased from BD (Franklin Lakes, NJ). CD206 antibody was
purchased from ABD Serotec (Raleigh, NC). Collagen antibody
was purchased from Abcam (Cambridge, MA).
Pulmonary fibrosis model
2 million vaccinia particles were administered intransally on day
27. .025 U of bleomycin was administered on day 0 by tracheal
cutdown. Mice were sacrificed at various intervals, lungs were
exsanguinated, removed, processed to single cell suspensions, and
stimulated in vitro with PMA and Ionomycin.
Flow cytometry
All flow cytometry was performed on a FacsCaliber, BD
Biosciences (San Jose, CA).
ELISA
IFNc ELISA was performed according to manufacturer’s
protocol, ebioscience (San Jose, CA).
Collagen assay
Hydroxyproline assay was performed according to manufac-
turer’s protocol, biovision (San Francisco, CA).
Histology
Lungs were inflated to pressure with formalin, sectioned and
stained for H&E. Samples were analyzed by microscope at 106
magnification.
Real Time PCR
RNA was isolated using Trizol reagent, Invitrogen (Carlsbad,
CA). Real Time PCR was performed using reagents purchased
from Applied Biosystems. Real Time PCR was performed on
a 7500 system Applied Biosystems (Carlsbad, CA).
Statistical analysis
All statistical analysis was conducted using the paired Student’s
t-test. Statistical significant values were those where p,0.05.
Supporting Information
Figure S1 Intranasal vaccinia administration induces T
cell recruitment to the lung. Thy1.1
+ OT-II
+ T cells were
transferred intravenously into wild type recipients. The next day
mice received 2610
‘6 vaccinia viral particles or PBS intranasally.
Three days later lungs were isolated, processed to single cell
suspensions and flow cytometry was performed in order to
determine percentages of Thy1.1
+ OT-II
+ lung T cells. All
experiments were performed at least three times, at least 10
animals per group per experiment.
(TIF)
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